Kusajili – Centralise les essais cliniques mondiaux

Résultat de votre recherche par promoteur : Ipsen Group, SCRAS Institut Henri Beaufour

Femme et Homme Max 99 ans
Ipsen Group, SCRAS Institut Henri Beaufour MAJ Il y a 4 ans

A Phase II, Randomised, Double-Blind Study to Compare the Safety and Efficacy of One Treatment Cycle of Clostridium Botulinum Type A Toxin (50 Units) When Reconstituted from Either a 125 Unit or a 500 Unit Presentation for the Treatment of Glabellar Lines The main objective is the assessment of the relative clinical safety of the two different presentations (125 U vial (referred to as Reloxin) and 500 U vial (Dysport®)) by comparison of the incidence a...

Pays Aucun
Organes Aucun
Spécialités Aucune

Essai clos aux inclusions

Plus d'informations